Open AccessIn vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria
Author(s) -
Anandi Martin,
Isabel Torres Godino,
Diana A. Aguilar-Ayala,
Vanessa Mathys,
Nacer Lounis,
Hector Rodríguez-Villalobos
Publication year - 2019
Publication title -
journal of medical microbiology/journal of medical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.91
H-Index - 117
eISSN - 1473-5644
pISSN - 0022-2615
DOI - 10.1099/jmm.0.001025
Subject(s) - bedaquiline , microbiology and biotechnology , nontuberculous mycobacteria , mycobacterium , resazurin , mycobacterium tuberculosis , biology , agar , mycobacterium kansasii , antimycobacterial , antibiotics , tuberculosis , bacteria , medicine , pathology , genetics
Bedaquiline (BDQ) is a recently approved antibiotic for the treatment of multidrug-resistant tuberculosis, but its potential against slow-growing mycobacteria (SGM) is still unknown. The objective of this study was to determine the in vitro activity of BDQ on SGM by assessing their MIC and minimal bactericidal concentration (MBC). The MIC of BDQ against 17 clinical isolates including Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium chimaera, Mycobacterium kansasii and Mycobacterium simiae species was determined by the resazurin microtitre assay and the MBC by the c.f.u. determination on 7H10 agar plates. BDQ has a bacteriostatic activity on all SGM tested with a MIC range from 0.03 to 0.007 µg ml -1 and surprisingly a good bactericidal activity on the majority of the isolates tested with an MBC of 1-2 µg ml -1 . Based on these preliminary results BDQ seems to be very promising for treatment of diseases caused by SGM.